Perioperative medication management (anticoagulants, antiplatelets, diabetes drugs, steroids; bridging)
Bedside summary
Structured management of chronic medications around surgery balances thrombotic/decompensation risk against surgical bleeding risk. Core decisions: whether and when to stop/restart anticoagulants and antiplatelets (and whether to bridge), how to manage diabetes medication and glycaemia, whether perioperative steroid cover is needed, and which other high-risk drugs (ACEi/ARB, SGLT2 inhibitors, HRT, DMARDs) to adjust. This is a DRAFT framework — always individualise to procedure bleeding risk, patient thrombotic risk and local anaesthetic/surgical protocol.
Red flags
- Recent coronary stent (esp. <1-3 months drug-eluting) — stopping antiplatelets risks stent thrombosis; involve cardiology, defer elective surgery
- Mechanical heart valve or VTE within 3 months — high thrombotic risk, bridging usually required
- Emergency surgery on a DOAC/warfarin — needs reversal (idarucizumab for dabigatran, andexanet/PCC for factor Xa inhibitors, PCC + vitamin K for warfarin)
- Patient on long-term steroids presenting unwell/hypotensive — adrenal crisis, give stress-dose hydrocortisone
- Euglycaemic DKA in an SGLT2-inhibitor patient fasted for surgery
Assessment
Differential diagnosis
- Decision drivers: procedure bleeding risk (low vs high), neuraxial anaesthesia planned, patient thrombotic risk (mechanical valve, recent VTE/stroke, AF CHA2DS2-VASc, recent coronary stent), renal function, urgency (elective vs emergency)
Investigations
- Reconcile all medicines; establish indication and thrombotic risk for anticoagulant/antiplatelet
- U&E/eGFR (DOAC stop timing is renal-dependent), FBC, coagulation; INR for warfarin (target <1.5 for most surgery)
- HbA1c / recent glucose control; capillary glucose perioperatively +/- ketones (SGLT2i)
- Group & save/crossmatch per procedure; assess need for steroid cover (dose & duration of exogenous steroid)
Management
- WARFARIN: stop ~5 days before surgery; check INR day before (aim <1.5). Bridge with therapeutic LMWH ONLY if high thrombotic risk (e.g. mechanical mitral valve, VTE <3 months, recent stroke) — most AF patients do NOT need bridging (BRIDGE trial). Restart warfarin evening of surgery/next day; give prophylactic/therapeutic LMWH until INR therapeutic
- DOACs: do NOT routinely bridge. Stop based on drug, renal function and bleeding risk — typically 24-48 h before (apixaban/rivaroxaban/edoxaban ~24 h low-risk, ~48 h high-risk; longer if eGFR low; dabigatran longer if renal impairment). Restart 24-48 h post-op once haemostasis secure; cover with prophylactic LMWH if oral delayed [verify local pathway]
- ANTIPLATELETS: continue aspirin for most surgery (especially secondary prevention/stent). Do NOT stop dual antiplatelet therapy electively within 3 months (bare-metal/old) to 6-12 months of a coronary stent without cardiology discussion — defer elective surgery if possible; continue aspirin, stop P2Y12 inhibitor (clopidogrel ~5-7 days, ticagrelor ~3-5 days, prasugrel ~7 days) per surgical bleeding risk
- DIABETES: for day-case/minor, manipulate usual regimen and monitor. Omit SGLT2 inhibitors >=3 days before surgery (euglycaemic DKA risk). Omit metformin on day of surgery if contrast/long fast/AKI risk. Reduce/adjust insulin (e.g. 20% reduction of long-acting the night before/day of). Use variable-rate IV insulin infusion (VRIII) for prolonged fasting/poor control/major surgery. Target glucose ~6-10 mmol/L
- STEROIDS: patients on long-term steroids (>=5 mg prednisolone daily for weeks, or recent high-dose) need perioperative glucocorticoid cover to prevent adrenal crisis — give usual dose plus additional hydrocortisone per surgical stress
- OTHER: consider withholding ACEi/ARB on morning of surgery (intra-op hypotension); continue beta-blockers; manage HRT/COCP VTE risk; hold methotrexate/biologics per rheumatology if infection/wound concern
- Document a clear stop/restart plan and communicate to surgical/anaesthetic team and patient
Drugs & doses
Disposition
Complications & pitfalls
- Surgical bleeding / haematoma (inadequate stop interval) vs thrombosis (over-cautious stopping or unnecessary bridging — bridging increases bleeding)
- Stent thrombosis / MI from premature antiplatelet cessation
- Perioperative hypo- or hyperglycaemia, DKA (SGLT2i)
- Adrenal crisis from inadequate steroid cover; spinal/epidural haematoma from mistimed anticoagulation
Exam pearls
- Bridging causes more harm than good in most AF patients (BRIDGE trial) — reserve it for genuinely high thrombotic risk.
- DOACs do not need bridging — rely on predictable pharmacokinetics; stop timing is renal-dependent (PAUSE study).
- Stop SGLT2 inhibitors >=3 days before surgery to avoid euglycaemic DKA.
- Never stop dual antiplatelet therapy early after a recent stent without cardiology input.
- Guidance: NICE NG89 (perioperative VTE), BSH/ACC/ESC periprocedural anticoagulation, Joint British Diabetes Societies (JBDS) inpatient surgery guidance, Association of Anaesthetists steroid cover guidance. Verify every timing against local protocol.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.